• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Economy

XAIR Stock Price Target and Forecast for 2024

by August 21, 2024
written by August 21, 2024

Is XAIR Stock a Buy or Sell? Latest Predictions

Today’s XAIR stock price stands at $0.4597, trading higher by $0.0397 (+9.4524%) in this session. Beyond Air, Inc. is a biopharmaceutical and medical device company in the commercial stage. It established the Lungfit system, creating a nitric oxide (NO) generator and delivery method tool. 

Beyond Cancer and Beyond Air are its two operating segments. The company treats newborns with persistent pulmonary hypertension with Lungfit PH. Moreover, it is developing LungFit GO to treat nontuberculous mycobacteria, along with LungFit PRO for treating viral lung infections. 

These infections include bronchiolitis and community-acquired pneumonia (COVID-19) in hospitalised patients. Additionally, the business is working on ultra-high concentration NO for solid tumour treatment in the Phase 1 clinical trial. 

It has partnered with the Hebrew University of Jerusalem, LLTD’s Yissum Research Development Company, to purchase the commercial rights to neuronal nitric oxide synthase inhibitors. The doctors use the latter for treating neurological disorders like autism spectrum disorder. 

The company, which first entered the market in 2011 under the name AIT Therapeutics, Inc., established its headquarters in Garden City, New York. In June 2019, it rebranded to Beyond Air, Inc., reflecting a shift in focus and strategy. For investors, this stock may be appealing due to the company’s evolving business model and its potential for growth, as evidenced by its rebranding efforts and continuous development within its industry.

XAIR Stock Price Prediction

In the latest XAIR stock forecast, Wall Street analysts have set an average price target of $3.75 for Beyond Air Inc. This projection is based on three separate 12-month price targets issued within the past three months. The analysts’ estimates range from a low of $3.50 to a high of $4.00. Notably, the average target price of $3.75 represents a significant 792.86% increase from the current price of $0.42.

The sales forecast for the upcoming quarter is $881.00K, with a price range of $784.00K to $1.05M. Moreover, sales for the preceding quarter totalled $470.00K. 

Over the last 12 months, XAIR has exceeded its sales projections by 0.00%, while the industry has surpassed sales projections by 46.68% during the same period. This means XAIR did not perform as well as its industry in the previous calendar year. Consequently, the earnings estimate for Beyond Air stock for the upcoming quarter is -$0.34, with a price range of -$0.40 to -$0.28. The EPS for the prior quarter was also -$0.36.

On the other hand,  XAIR has outperformed its estimated profit percentage (75.00%) over the last 12 months, while the industry has exceeded its estimate by 57.28% during the same period. Thus, over the past year, this stock has outperformed its rivals on the market. 

XAIR/USD 5 DAY-Chart

XAIR Stock News

Here are the newest figures of the Beyond Air Stock: 

Profit Margin: 0.00%
Operating Margin: -1,988.43%
Return on Assets: -63.48%
Return on Equity: -219.18%
Revenue: 1.78M
Revenue Per Share: 0.05
Quarterly Revenue Growth: 1,057.60%
EBITDA: -58.36M
Net Income Avi to Common: -58.35M
Diluted EPS: -1.6400
Total Cash: 21.37M
XAIR Total Cash Per Share: 0.46
Total Debt: 17.7M
Total Debt/Equity: 100.01%
Current Ratio: 2.63
Book Value Per Share: 0.35
Operating Cash Flow: -49.04M
Levered Free Cash Flow: -25.8M
52 Week Range: -88.40%
S&P 500 52-Week Change: 19.16%
52 Week High: 3.9000
52 Week Low: 0.4150
50-Day Moving Average: 0.8111
200-Day Moving Average: 1.4368
Average Vol (3 months): 824.12k
Average Vol (10 days): 440.23k
Shares Outstanding: 45.9M
Implied Shares Outstanding: 45.9M
Float: 34.38M
Percentage  Held by Insiders: 18.44%
Percentage  Held by Institutions: 35.36%
Shares Short (7/15/2024): 1.06M
Short Ratio (7/15/2024): 0.57
XAIR Short % of Float (7/15/2024): 2.61%
Short % of Shares Outstanding (7/15/2024): 2.31%
Shares Short (prior month 6/14/2024): 3.37M

Is XAIR Stock Buy or Sell?

According to the technical indicators, XAIR is currently rated as a Strong Sell. The 20-day EMA for the stock is 0.77, but its share price has dropped to $0.42. However, the Moving Averages Convergence Divergence (MACD) index for Beyond Air Inc. (XAIR) stands at -0.17, indicating a potential Buy.

This divergence in opinion could stem from the stock’s current low price, which might appeal to bargain hunters looking for an undervalued investment. Additionally, the company’s diversification into multiple medical sectors could offer long-term growth opportunities, making it an attractive option for investors willing to take on some risk.

XAIR Stock Market: The Fiscal 1st Quarter’s Earnings

XAIR earnings for the fiscal quarter that ended June 30, 2024, were $0.7 million. For comparison, the company reported $0.1 million in earnings for the fiscal quarter ending June 30, 2023, and $0.5 million for the previous quarter ending March 31, 2024.

For the three months ending June 30, 2024, the cost of revenue stood at $1.0 million, as opposed to $0.3 million for the same period in 2023. Thus, the cost of revenue exceeded the revenue itself. The experts think that the depreciation of LungFit devices caused this downfall. 

Expenses related to research and development reached $6.0 million in the three months ending June 30, 2024, while the company spent $4.7 million for the same period in 2023. 

The team also noted a reduction in stock compensation expenses by $0.6 million ($0.2 million for Beyond Cancer and $0.4 million for Beyond Air) and a $0.3 million decrease in growth rate costs for Beyond Cancer research, alongside a $0.9 million increase in salaries ($0.3 million for Beyond Air and $0.6 million for Beyond Cancer).

Despite this data, the consensus for this stock is currently a moderate Buy. If it declines further or reports more losses, that rating might change, though. However, its low price and the company’s diversification across various medical sectors may still make it appealing to long-term investors who are willing to take on some risk in the hopes of future growth potential.

The post XAIR Stock Price Target and Forecast for 2024 appeared first on FinanceBrokerage.

0 comment
0
FacebookTwitterPinterestEmail

previous post
Dogecoin and Shiba Inu: Dogecoin is firmly above EMA 200
next post
DRCT Stock: Direct Digital Holdings Price Forecast

related articles

Oil Prices Rebound After Trump’s Criticism of Powell

April 22, 2025

Trump’s Fed Criticism Sparks Investor Concerns

April 22, 2025

Buy Bitcoin Under $100K Before The Next Bull...

April 22, 2025

BNB Price Surge Leads Crypto Gains as Bitcoin...

April 21, 2025

Fed’s Stagflation Warning Impacts Crypto Markets

April 21, 2025

Bitcoin Slips to $83.6K Amid Nvidia’s $5.5B Charge

April 21, 2025

Gold Price Surge Hits $3,385 Amid Trade Tensions

April 21, 2025

Bitcoin Rebounds to $83,404 Amid Renewed Investor Confidence

April 21, 2025

Memecoins, AI, and DeFi Tokens Lead Crypto Rebound

April 21, 2025

Bitcoin Nears $85K Amid Market Optimism

April 21, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Trump plans to meet with Zelenskyy as he looks to end Ukraine war

    February 7, 2025
  • ‘Escape poverty’: Millions more food stamp recipients required to work under new House GOP proposal

    February 24, 2025
  • Nifty and German 40 are under pressure, falling to new lows

    August 6, 2024
  • Trump White House victory called ‘the greatest political comeback in American history’

    November 6, 2024
  • SCOOP: Trump ally’s Gulf of America bill sparks frustration in House GOP

    May 6, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (4,735)
  • Investing (624)
  • Stock (775)

Latest Posts

  • Dogecoin and the Shiba Inu: new step back for Dogecoin

    August 15, 2024
  • Walz says Harris picked him for VP to ‘code talk to White guys’

    April 30, 2025
  • Tension over upstate New York race helps put Elise Stefanik Trump role in jeopardy

    March 27, 2025

Recent Posts

  • Trump bans federal funding for ‘dangerous’ gain-of-function research

    May 5, 2025
  • Former British PM reveals which Trump department is perfect ‘playbook’ for conservative revolution

    February 22, 2025
  • CPAC straw poll reveals who conservatives believe will be 2028 presidential nominee

    February 22, 2025

Editor’s Pick

  • Business is good in ‘Vacationland.’ It would be even better with more housing.

    August 5, 2024
  • With 16 days until voting starts, ‘election season’ kicks off sooner than you think

    August 21, 2024
  • ApeCoin and the Akita Inu: Akita Inu continues to retreat

    July 24, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock